RxDoctor Payments Data

Eric Solomon, DO

Physical Medicine & Rehabilitation · Marietta, GANPI 1740267640

Payments from drug & device makers

$812in general payments, 2019–2025

Across 47 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$176
  • Lilly USA, LLC$118
  • Amgen$117
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$71
  • AbbVie$64
  • Biohaven Pharmaceuticals, Inc.$64
  • plus $202 from 9 others
$125in research payments, 2019–2025

Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$125

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$812 in reported general payments places this provider in the 65th percentile of 214 physical medicine & rehabilitation providers in Georgia.

See all physical medicine & rehabilitation providers in Georgia

Medicare billing

Part B allowed, 2024
$370,150
Medicare patients
110
Services billed
4,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe46$33,793
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen956$28,744
OxycontinOxycodone Hcl34$24,603
Xtampza ErOxycodone Myristate31$15,628
Oxycodone Hcl660$13,116
Lidocaine76$12,390
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen419$9,141
Tramadol Hcl692$8,436
Gabapentin537$6,990
Fentanyl36$6,484
MovantikNaloxegol Oxalate15$6,261
Tizanidine Hcl398$5,138
Diclofenac Sodium191$4,215
Cyclobenzaprine Hcl283$2,709
Morphine Sulfate ErMorphine Sulfate101$2,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$44$15,62831 claims
Redhill Biopharma Inc.Movantik$29$6,26115 claims
Virtus Pharmaceuticals LLCLactulose$13$46913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 214 physical medicine & rehabilitation providers in Georgia.

Other physical medicine & rehabilitation in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →